Polaryx Therapeutics Inc(PLYX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.14 | Insider Own | 87.33% | Shs Outstand | 49.9M | Perf Week | -4.12% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | -55.36% | Insider Trans | 0.2% | Shs Float | 6.3M | Perf Month | -10.14% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.04 | Inst Own | 4.4% | Short Float | 1.87% | Perf Quarter | -19.48% |
| Income | -0.01B | P/S | - | EPS this Y | 6.67% | Inst Trans | -1.12% | Short Ratio | 1.9 | Perf Half Y | -64.57% |
| Sales | 0.00B | P/B | 8.48 | EPS next 5Y | -21.27% | ROA | -89.21% | Short Interest | 0.12M | Perf YTD | -95.87% |
| Book/sh | 0.22 | P/C | 8.03 | EPS past 3/5Y | -54.22% - | ROE | -96.56% | 52W High | -96.2% ($48.91) | Perf Year | - |
| Cash/sh | 0.23 | P/FCF | - | Sales past 3/5Y | - | ROIC | -62.61% | 52W Low | 5.98% ($1.75) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 9.65% | Gross Margin | - | Volatility(W/M) | 5.37% 5.48% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.53 | EPS Q/Q | -34.27% | Profit Margin | - | RSI (14) | 39.78 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.53 | Sales Q/Q | - | SMA20 | -4.86% ($1.96) | Beta | - | Target Price | $7.67 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -7.63% ($2.01) | Rel Volume | 0.25 | Prev Close | $1.89 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -49.22% ($3.66) | Avg Volume(3M) | 0.06M | Price | $1.86 |
| IPO | 2026/2/2 | Option/Short | No/Yes | Trades | 114 | Volume | 15,388 | Change | -1.59% |
🧬 Polarix Therapeutics is a clinical-stage biopharmaceutical company developing treatments that target rare hereditary neurodegenerative diseases. The company is researching drug candidates aimed at unmet medical needs in areas such as lysosomal storage disorders and pediatric central nervous system diseases, and maintains an R&D-focused structure with no commercial products on the market yet.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 25% of its average volume.
PLYX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +6.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #369 of 594 in the industry
Based on market cap of $93M.
NRXS#366 Neuraxis Inc $95M PER - 
ICCC#367 Immucell Corp $94M PER 123.0 
COYA#368 Coya Therapeutics Inc $93M PER - PLYX#369 Polaryx Therapeutics Inc $93M PER - 
TNYA#370 Tenaya Therapeutics Inc $91M PER - 
FAQ
What kind of company is PLYX?
PLYX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLYX?
The market cap of PLYX is approximately $93M, ranking 4,516 within its sector.
What is the 52-week high and low for PLYX?
PLYX has recorded a 52-week high of $48.91 and a low of $1.75.
